Monday, June 11, 2007

Myriad Genetics (MYGN) Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimer's Conference


Current Flurizan™ Phase 3 Study Design May Demonstrate Disease Modification

Read the entire release at The Alzheimer's Reading Room